卡泊三醇/二丙酸倍他米松PAD乳膏治疗斑块状银屑病的汇总分析
本文汇总了两项3期随机对照试验,比较新型卡泊三醇/二丙酸倍他米松PAD乳膏与市售混悬凝胶/凝胶治疗斑块状银屑病的疗效与安全性。治疗8周后,PAD乳膏在PGA成功率、mPASI改善和DLQI 0/1应答上均显著优于对照,安全性相当。
要点
- PAD乳膏8周PGA成功率43.2%,高于对照的31.9%(P<0.0001)。
- PAD乳膏mPASI平均改善64.6%,优于对照的56.4%(P<0.0001)。
- PAD乳膏DLQI 0/1应答率43.8%,优于对照的34.2%(P=0.0005)。
核心结论
- 新型卡泊三醇/二丙酸倍他米松PAD乳膏治疗斑块状银屑病疗效优于市售混悬凝胶/凝胶,生活质量改善更佳,安全性相当。
研究设计与样本
- 汇总分析两项3期、多中心、随机、研究者盲法、阳性药与赋形剂对照试验,纳入银屑病患者。
- 研究产品包括PAD乳膏、活性对照(市售卡泊三醇/二丙酸倍他米松混悬凝胶/凝胶)和乳膏赋形剂,每日一次外用8周。
主要发现
- PAD乳膏组PGA治疗成功率为43.2%,对照混悬凝胶/凝胶组为31.9%(P<0.0001)。
- PAD乳膏组mPASI平均改善64.6%,对照混悬凝胶/凝胶组为56.4%(P<0.0001)。
- PAD乳膏组DLQI 0/1应答率为43.8%,对照混悬凝胶/凝胶组为34.2%(P=0.0005)。
- 与PAD乳膏相关的不良药物反应报告中,未出现频率>1%的事件。
关键数值与推荐
- PGA治疗成功:PAD乳膏43.2% vs 对照31.9%(P<0.0001)。
- mPASI平均改善百分比:PAD乳膏64.6% vs 对照56.4%(P<0.0001)。
- DLQI 0/1应答率:PAD乳膏43.8% vs 对照34.2%(P=0.0005)。
临床怎么用
- 对于适合外用治疗的斑块状银屑病患者,可优先选择卡泊三醇/二丙酸倍他米松PAD乳膏以提升疗效和生活质量。
局限性
- 汇总分析基于两项3期试验,结论需在更广泛真实世界人群中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plaque psoriasis is a common, chronic and relapsing inflammatory skin disease clinically characterized by erythema and scaling desquamation. As over 90% of psoriasis patients benefit from topical therapies, local treatments continue to play an eminent role in management strategies. One such topical treatment is the fixed dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP). OBJECTIVES: Pooled analysis of two different phase 3 clinical trails to compare superiority regarding efficacy, safety and quality of life (QoL) between CAL/BDP PAD-cream and CAL/BDP TS. METHODS: The data from two phase 3, multicentre, randomized, investigator-blind, active and vehicle-controlled trials enrolling patients with psoriasis were pooled and analysed. Investigational products included a CAL/BDP cream based on PAD™ Technology (PAD-cream) designed for high skin penetration and increased patient preference, an active control (marketed CAL/BDP topical suspension/gel, in the following abbreviated as CAL/BDP TS) and cream vehicle, which were applied once daily for 8 weeks. RESULTS: Efficacy and safety of the novel CAL/BDP PAD-cream formulation for the topical treatment of psoriasis demonstrated superiority for all efficacy end points after 8 weeks of treatment. PGA treatment success for CAL/BDP PAD-cream (43.2%) was greater than CAL/BDP TS (31.9%; P < 0.0001), the mean per cent reduction in mPASI for CAL/BDP PAD-cream was 64.6% compared to 56.4% for CAL/BDP TS (P < 0.0001) and DLQI 0/1 was obtained by 43.8% in the CAL/BDP PAD-cream group versus 34.2% in the CAL/BDP TS group (P = 0.0005). There was no adverse drug reaction reported with a frequency of >1%, associated with the CAL/BDP PAD-cream. CONCLUSIONS: The novel fixed dose combination CAL/BDP PAD-cream offers greater efficacy, superior patient QoL and equivalent favourable safety for the topical treatment of psoriasis, in comparison to the currently available topical suspension/gel.
引用
- Pinter A, Green LJ, Selmer J, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2021. PMID: 34628687. doi:10.1111/jdv.17734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。